International Stem Cell Corporation Insider Trading

ISCO

Last 12 months

Insiders sold 10K and bought nothing on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan. Director Paul V Maier sold 10K on Sep 11, 100% of their stake, outside a plan. The last open-market buy by an executive or director was in Jan 2019.

Net open-market

−10K

0 buys · 1 sale

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

0 / 1

executives and directors

Last open-market buy

Jan 2019

Jan 21, 2019

Get an email when ISCO's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 11	Paul V Maier Director	SoldNo plan	32,802	$0.32	10K	100%	Form 4

Sep 11No plan
Paul V Maier
Director · sold 32,802 at $0.32
10K
100% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ISCO, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ISCO

CompareIntrinsic value

HOOKHookipa Pharma Inc.

No recent price20

PGENPrecigen Inc.

$5.06-3.71%0

IRDOpus Genetics Inc.

$4.27+8.65%10

EVMNEvommune, Inc.

$6.04+1.68%35

ZBIOZenas BioPharma, Inc.

$28.46+0.28%10

PTNPalatin Technologies, Inc.

$6.02+15.33%50

BIOABioAge Labs, Inc.

$5.95-0.17%10

ACRSAclaris Therapeutics, Inc.

$3.68-1.60%10

Spot a number that looks wrong? Check it in ISCO's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ISCO

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.